EUVIMED · CrossrefJournal
Seminars in Hematology
ISSN 0037-1963 · Elsevier BV
Latest articles
Ribosome Profiling: A Functional Genomics Approach to Study Translation in Hematologic Disease
Outcomes and challenges of stem cell transplantation in patients with ribosomopathies
Shwachman–Diamond syndrome: A paradigm for ribosomopathies, somatic genetic rescue, and leukemia predisposition syndrome
Ribosome structure, function and dysfunction at the molecular level
Gene-targeted therapies in inherited bone marrow failure syndromes
Gene therapy for hemoglobinopathies
Hematopoietic Proteostasis Across the Lifespan: From Fetal Development to Bone Marrow Failure
Sickle cell disease-specific barriers to in vivo hematopoietic stem cell gene therapy
MRD in multiple myeloma: From an early endpoint for accelerated approval to MRD driven treatment and clinical management
Emerging technologies for minimal residual disease detection in hematologic malignancies
Minimal residual disease guided treatment approaches in non-Hodgkin lymphoma—Where we are and where we’re headed
Targeted immunoPET imaging of multiple myeloma
Blood-based MRD testing in multiple myeloma: Update on mass spectrometry methods for detecting the monoclonal immunoglobulin
BCMA biology and therapeutic targeting in multiple myeloma: From ligand signaling to antigen escape
AML diagnostics in the 21st century: Use of AI
Epigenetic dysregulation in acute myeloid leukemia
Secondary and therapy-related acute myeloid leukemias: Overlapping features, distinct trajectories
The immunotherapy landscape in AML: Defining knowledge gaps toward rational combinatorial strategies
The role of 1q abnormalities in multiple myeloma: Genomic insights, clinical implications, and therapeutic challenges
Modernizing multiple myeloma clinical trial eligibility to improve equity and inclusivity by hematological parameters
Immunocompetent mouse models of multiple myeloma
Therapy-related myelodysplastic syndromes and acute myeloid leukemia
Intestinal microbiome and myelodysplastic syndromes: Current state of knowledge and perspectives for future
The biology of classical Hodgkin lymphoma
Therapeutic targeting of apoptosis in chronic lymphocytic leukemia
Targeting the B cell receptor signaling pathway in chronic lymphocytic leukemia
The crossroads of cancer therapies and clonal hematopoiesis
Clonal hematopoiesis and autoimmunity
TET2 mutation as prototypic clonal hematopoiesis lesion
DLBCL arising from indolent lymphomas: How are they different?
EUVIMED